Enter a player name to begin or load your saved progress.
Colonel Eli Lilly, the founder of the company, served as a veteran during the American Civil War.
Answer: True
Explanation: Colonel Eli Lilly, the founder of the pharmaceutical company, was indeed a veteran of the Union army during the American Civil War.
Eli Lilly and Company was founded in the late 19th century, specifically in 1876.
Answer: True
Explanation: The establishment date of Eli Lilly and Company is 1876, placing its founding in the latter part of the 19th century.
Colonel Eli Lilly's initial pharmaceutical product was quinine, utilized for the treatment of malaria.
Answer: True
Explanation: The first product manufactured and sold by Colonel Eli Lilly was quinine, a medication historically used to treat malaria.
Eli Lilly and Company was an early innovator in making medications more palatable, pioneering the use of fruit flavorings and sugar coatings for pills.
Answer: True
Explanation: Eli Lilly and Company introduced advancements such as fruit flavorings and sugar coatings to improve the palatability and ease of administration of its pills.
Succus Alteran, marketed as a 'blood purifier,' represented Eli Lilly and Company's first significant commercial success, not a failure.
Answer: True
Explanation: Succus Alteran, introduced in 1883 and promoted as a 'blood purifier,' marked Eli Lilly and Company's inaugural major commercial success.
Josiah K. Lilly Sr. significantly expanded the company's operations by organizing its research department and initiating international distribution.
Answer: True
Explanation: Under Josiah K. Lilly Sr.'s leadership, the company experienced substantial growth, notably through the formalization of its research department and the establishment of international distribution channels.
In the late 19th century, Eli Lilly and Company implemented straight-line production methods to enhance manufacturing efficiency.
Answer: True
Explanation: Eli Lilly and Company adopted straight-line production methodologies during the late 19th century as a strategy to improve operational efficiency.
Who founded Eli Lilly and Company in the year 1876?
Answer: Colonel Eli Lilly
Explanation: Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran, established Eli Lilly and Company in 1876.
What was the primary focus of Eli Lilly and Company upon its establishment in 1876?
Answer: Manufacturing pharmaceutical drugs, starting with quinine
Explanation: Upon its founding in 1876, Eli Lilly and Company's initial business focus was the manufacturing of pharmaceutical drugs, commencing with quinine.
Which innovation did Eli Lilly and Company introduce early in its history to enhance the palatability of its medicinal preparations?
Answer: Gelatin-coating for pills
Explanation: Eli Lilly and Company pioneered innovations such as gelatin-coating for pills, alongside flavorings and sugar coatings, to improve medication palatability.
What was the historical significance of Succus Alteran for Eli Lilly and Company during the late 19th century?
Answer: It was the company's first widely successful product, marketed as a 'blood purifier'.
Explanation: Succus Alteran, introduced in 1883, represented Eli Lilly and Company's first major commercial success, promoted as a 'blood purifier'.
Under the leadership of Josiah K. Lilly Sr., which key areas of the company experienced substantial expansion?
Answer: Research department and international distribution
Explanation: Josiah K. Lilly Sr.'s leadership saw significant expansion in the company's research department and the initiation of international distribution.
Eli Lilly and Company's primary business operations encompass the research, development, manufacturing, and marketing of pharmaceutical drugs.
Answer: True
Explanation: Eli Lilly and Company's core business activities are centered on the comprehensive process of developing, producing, and distributing pharmaceutical drugs.
Tirzepatide, marketed as Mounjaro and Zepbound, was the leading revenue-generating product for Eli Lilly in 2024, contributing approximately 37% of total sales.
Answer: True
Explanation: Tirzepatide, sold under the brand names Mounjaro and Zepbound, emerged as Eli Lilly's top revenue-generating product in 2024, accounting for approximately 37% of its sales.
Eli Lilly and Company holds the distinction of being the first entity to successfully mass-produce insulin.
Answer: True
Explanation: Eli Lilly and Company was the pioneering company in the large-scale commercial production of insulin.
Dulaglutide, marketed as Trulicity, is a key Eli Lilly product used for the treatment of type 2 diabetes, not breast cancer. Taltz (ixekizumab) is used for autoimmune diseases.
Answer: True
Explanation: Dulaglutide (Trulicity) is indicated for type 2 diabetes management, while Taltz (ixekizumab) is prescribed for autoimmune conditions. Neither is primarily used for breast cancer treatment.
Prozac (fluoxetine), developed by Eli Lilly and Company, achieved substantial commercial success as a treatment for depression.
Answer: True
Explanation: The development of Prozac (fluoxetine) by Eli Lilly and Company marked a significant commercial success, revolutionizing the treatment of depression.
Eli Lilly and Company's collaboration with University of Toronto scientists on insulin production significantly enhanced its market position, solidifying its role as a leading pharmaceutical manufacturer.
Answer: True
Explanation: The successful collaboration on insulin production with University of Toronto scientists greatly strengthened Eli Lilly and Company's market standing and reputation as a research-driven pharmaceutical leader.
Prozac experienced the expiration of its U.S. patent protection in 2001, subsequently becoming available as a generic medication.
Answer: True
Explanation: The patent protection for Prozac in the United States concluded in 2001, paving the way for its availability as a generic pharmaceutical.
In 2023, Eli Lilly announced a cap of $35 per month on out-of-pocket costs for its insulin products, applicable to individuals with commercial insurance, as part of its Insulin Value Program.
Answer: True
Explanation: As part of its Insulin Value Program, Eli Lilly committed in 2023 to capping the monthly out-of-pocket expense for its insulin products at $35 for eligible commercially insured patients.
Eli Lilly acquired the manufacturing rights for Bovine Somatotropin (bGH), a substance used to increase milk production in dairy cattle, from Monsanto in 2008.
Answer: True
Explanation: In 2008, Eli Lilly purchased the rights to manufacture Bovine Somatotropin (bGH) from Monsanto, a product intended to enhance milk yield in dairy cows.
Following the 1989 Standard Gravure shooting incident, Eli Lilly faced lawsuits and public scrutiny linking Prozac to allegations of abnormal behaviors and potential side effects.
Answer: True
Explanation: Prozac became the subject of legal challenges and public debate after the 1989 Standard Gravure incident, with accusations linking it to abnormal behaviors and adverse effects.
In 2004, the FDA mandated 'black box' warnings on antidepressants for increased risks of suicidal thoughts and behaviors in children and adolescents, later extending these warnings to young adults up to age 25.
Answer: True
Explanation: The FDA implemented 'black box' warnings on antidepressants, initially for pediatric populations in 2004 and subsequently for young adults up to age 25, due to heightened risks of suicidal ideation.
The acquisition of Loxo Oncology by Eli Lilly in 2019 represented a strategic move that substantially expanded the company's portfolio in the domain of targeted cancer therapies.
Answer: True
Explanation: Eli Lilly's 2019 acquisition of Loxo Oncology significantly enhanced its oncology offerings, particularly in the area of targeted cancer therapies.
Eli Lilly and Company developed bamlanivimab and bebtelovimab, which were utilized as treatments for COVID-19.
Answer: True
Explanation: Bamlanivimab and bebtelovimab are therapeutic agents developed by Eli Lilly and Company for the treatment of COVID-19.
Tirzepatide, marketed as Mounjaro and Zepbound, is approved for the treatment of type 2 diabetes and obesity, not exclusively for diabetes.
Answer: True
Explanation: Tirzepatide (Mounjaro/Zepbound) has received regulatory approval for both type 2 diabetes and obesity management, extending beyond solely diabetes treatment.
Eli Lilly and Company manufactured a significant portion, approximately 60%, of the Salk polio vaccine for clinical trials and distribution in 1954-1955, but not 100%.
Answer: True
Explanation: While Eli Lilly and Company played a crucial role in producing the Salk polio vaccine, manufacturing approximately 60% of it, it did not produce 100% for the trials.
During the 1970s and 1980s, Eli Lilly and Company introduced several significant pharmaceutical products, including the antibiotics Keflex and Ceclor.
Answer: True
Explanation: The periods of the 1970s and 1980s saw Eli Lilly and Company release notable medications such as the antibiotics Keflex and Ceclor.
Donanemab, marketed as Kisunla, received regulatory approval in 2024 and is indicated for the treatment of Alzheimer's disease.
Answer: True
Explanation: Donanemab, known commercially as Kisunla, obtained regulatory approval in 2024 and is prescribed for patients diagnosed with Alzheimer's disease.
The Lilly Insulin Value Program enables individuals with commercial insurance to cap their monthly out-of-pocket expenses for any Lilly insulin prescription at $35.
Answer: True
Explanation: The Lilly Insulin Value Program is designed to limit the monthly out-of-pocket cost for commercially insured individuals to $35 for any prescription of Lilly's insulin products.
Eli Lilly formed a joint venture with Icos, the developer of Cialis, in 1998 and later acquired the company outright in 2007, rather than acquiring it directly in 1998.
Answer: True
Explanation: Eli Lilly's involvement with Cialis began with a joint venture with Icos in 1998, culminating in the full acquisition of Icos in 2007.
Cymbalta (duloxetine), developed by Eli Lilly, is primarily indicated for the treatment of major depressive disorders and anxiety, among other conditions.
Answer: True
Explanation: Cymbalta (duloxetine), a product of Eli Lilly, is primarily prescribed for major depressive disorder and anxiety, with applications in managing other conditions as well.
Eli Lilly acquired Armo Biosciences in 2018 to enhance its oncology pipeline, particularly its immuno-oncology capabilities, not specifically its vaccine development.
Answer: True
Explanation: The acquisition of Armo Biosciences by Eli Lilly in 2018 was aimed at strengthening its oncology pipeline, specifically in the area of immuno-oncology.
Eli Lilly and Company introduced exenatide in 2005, marking the market debut of the first GLP-1 receptor agonist.
Answer: True
Explanation: Exenatide, brought to market by Eli Lilly and Company in 2005, was the inaugural GLP-1 receptor agonist available to patients.
Eli Lilly and Company developed Liver Extract No. 55 in collaboration with scientists from the University of Rochester, following earlier work with Harvard scientists on Liver Extract 343.
Answer: True
Explanation: Liver Extract No. 55 was developed by Eli Lilly in conjunction with University of Rochester researchers, building upon prior collaborations with Harvard scientists.
The acquisition of CoLucid Pharmaceuticals by Eli Lilly provided the company with lasmiditan, a late-stage clinical candidate targeting the treatment of migraines.
Answer: True
Explanation: Through the acquisition of CoLucid Pharmaceuticals, Eli Lilly gained access to lasmiditan, a promising late-stage candidate for migraine therapy.
What is the primary business focus of Eli Lilly and Company?
Answer: Developing, manufacturing, and selling pharmaceutical drugs.
Explanation: Eli Lilly and Company's core business operations are centered on the research, development, manufacturing, and commercialization of pharmaceutical drugs.
Which specific product was the largest contributor to Eli Lilly's 2024 revenue, accounting for 37% of sales?
Answer: Tirzepatide (Mounjaro/Zepbound)
Explanation: Tirzepatide, marketed as Mounjaro and Zepbound, was Eli Lilly's top revenue-generating product in 2024, representing 37% of its sales.
Which of the following is NOT identified as a historical milestone achieved by Eli Lilly and Company in the fields of vaccine or insulin production?
Answer: Developed the first mRNA vaccine.
Explanation: While Eli Lilly has milestones in insulin and polio vaccine production, the development of the first mRNA vaccine is not attributed to the company.
What seminal drug for the treatment of depression was introduced by Eli Lilly and Company in 1988?
Answer: Prozac (fluoxetine)
Explanation: In 1988, Eli Lilly and Company introduced Prozac (fluoxetine), a groundbreaking medication for depression.
What was the impact of Eli Lilly and Company's collaboration on insulin production on its market standing?
Answer: It significantly boosted the company's standing as a leading research-based manufacturer.
Explanation: The successful large-scale production of insulin, achieved through collaboration, substantially enhanced Eli Lilly and Company's market position and reputation.
What significant action did Eli Lilly take in 2023 concerning the out-of-pocket cost of its insulin products for eligible patients?
Answer: Capped the out-of-pocket cost at $35 per month.
Explanation: In 2023, Eli Lilly announced it would cap the out-of-pocket cost for its insulin products at $35 per month for eligible patients.
What controversy surrounds Bovine Somatotropin (bGH), and what role did Eli Lilly play concerning its manufacturing rights?
Answer: bGH is used to increase milk production in dairy cattle and Lilly purchased manufacturing rights.
Explanation: Bovine Somatotropin (bGH) is used to enhance milk production in dairy cattle, and Eli Lilly acquired its manufacturing rights from Monsanto.
Which medication, developed by Eli Lilly and Company, faced significant legal and public relations challenges due to allegations linking it to abnormal behaviors?
Answer: Prozac (Fluoxetine)
Explanation: Prozac (Fluoxetine), developed by Eli Lilly, encountered substantial legal and public relations challenges stemming from allegations connecting it to abnormal behaviors.
The FDA mandated 'black box' warnings on antidepressants due to increased risks of suicidal thoughts. For which specific age demographic were these warnings initially mandated in 2004?
Answer: Children and adolescents
Explanation: In 2004, the FDA initially mandated 'black box' warnings on antidepressants for children and adolescents due to elevated risks of suicidal thoughts.
What was the strategic significance of Eli Lilly's acquisition of Loxo Oncology in 2019?
Answer: It significantly bolstered Lilly's oncology portfolio with targeted therapies.
Explanation: The acquisition of Loxo Oncology in 2019 was strategically significant for Eli Lilly, substantially enhancing its oncology portfolio with targeted therapies.
Which pharmaceutical agent, introduced by Eli Lilly in 2005, marked the market debut of the GLP-1 receptor agonist class?
Answer: Exenatide
Explanation: Exenatide, launched by Eli Lilly in 2005, was the first drug in the GLP-1 receptor agonist class.
What is the therapeutic indication for Donanemab, marketed as Kisunla, which received approval in 2024?
Answer: Treatment of Alzheimer's disease
Explanation: Donanemab (Kisunla), approved in 2024, is indicated for the treatment of Alzheimer's disease.
What was Eli Lilly and Company's role in the development and commercialization of Cialis?
Answer: Formed a joint venture with Icos in 1998 and later acquired the company.
Explanation: Eli Lilly and Company partnered with Icos through a joint venture in 1998 for Cialis development and later acquired Icos in 2007.
What was the primary strategic significance of Eli Lilly's acquisition of CoLucid Pharmaceuticals?
Answer: Gained a late-stage clinical candidate for migraine treatment.
Explanation: The acquisition of CoLucid Pharmaceuticals provided Eli Lilly with lasmiditan, a late-stage clinical candidate for the treatment of migraines.
Eli Lilly and Company's stock is listed and traded on the New York Stock Exchange (NYSE) under the ticker symbol LLY.
Answer: True
Explanation: Eli Lilly and Company's stock is publicly traded on the New York Stock Exchange (NYSE), with the ticker symbol LLY.
David A. Ricks currently holds the positions of Chair, President, and Chief Executive Officer at Eli Lilly and Company.
Answer: True
Explanation: David A. Ricks is the current executive leader of Eli Lilly and Company, serving concurrently as its Chair, President, and Chief Executive Officer.
The Lilly Endowment, a charitable foundation, maintains a significant minority ownership stake in Eli Lilly and Company, holding 10.8% of its outstanding stock.
Answer: True
Explanation: The Lilly Endowment, a philanthropic entity established by the founding family, holds a 10.8% minority stake in Eli Lilly and Company's stock.
Eugene N. Beesley was the first non-family member appointed as president of Eli Lilly and Company in 1953, marking a significant transition in leadership.
Answer: True
Explanation: The appointment of Eugene N. Beesley as president in 1953 represented a pivotal moment, as he was the first individual outside the founding family to hold this leadership position.
The Lilly Endowment's ownership stake in Eli Lilly and Company, while significant, is primarily rooted in the founding family's philanthropic legacy rather than direct control over day-to-day voting rights in company decisions.
Answer: True
Explanation: The Lilly Endowment's ownership stake reflects its philanthropic origins and purpose, rather than serving as a mechanism for direct control over the company's operational voting rights.
The substantial ownership stake held by the Lilly Endowment in Eli Lilly and Company underscores the founding family's enduring commitment to philanthropic endeavors.
Answer: True
Explanation: The ownership of Eli Lilly and Company by the Lilly Endowment serves as a testament to the founding family's long-standing dedication to philanthropy.
In 1994, Eli Lilly and Company acquired PCS Systems, a significant entity in the realm of drug benefits and health maintenance organizations (HMOs).
Answer: True
Explanation: The acquisition of PCS Systems by Eli Lilly and Company in 1994 represented a strategic entry into the pharmacy benefit management sector.
On which major stock exchange is the common stock of Eli Lilly and Company listed and traded?
Answer: New York Stock Exchange (NYSE)
Explanation: The common stock of Eli Lilly and Company is traded on the New York Stock Exchange (NYSE).
As per the current information, who occupies the executive leadership roles of Chair, President, and Chief Executive Officer at Eli Lilly and Company?
Answer: David A. Ricks
Explanation: David A. Ricks currently serves as the Chair, President, and Chief Executive Officer of Eli Lilly and Company.
What proportion of Eli Lilly and Company's stock is held by the Lilly Endowment?
Answer: 10.8%
Explanation: The Lilly Endowment holds a 10.8% ownership stake in Eli Lilly and Company.
What pivotal transition in corporate leadership did the appointment of Eugene N. Beesley as president in 1953 signify for Eli Lilly and Company?
Answer: The first instance of a non-family member leading the company.
Explanation: Eugene N. Beesley's appointment as president in 1953 marked a significant shift, being the first time a non-family member assumed leadership of Eli Lilly and Company.
What is the primary significance attributed to the Lilly Endowment's ownership stake in Eli Lilly and Company?
Answer: It reflects the founding family's commitment to philanthropy.
Explanation: The Lilly Endowment's ownership stake is significant as it represents the founding family's deep-rooted commitment to philanthropy.
What strategic significance did the acquisition of PCS Systems by Eli Lilly and Company in 1994 hold?
Answer: It represented an entry into pharmacy benefit management.
Explanation: The 1994 acquisition of PCS Systems by Eli Lilly marked a strategic move into the pharmacy benefit management (PBM) sector.
In the fiscal year 2024, Eli Lilly and Company reported a consolidated revenue approximating US$45.04 billion.
Answer: True
Explanation: Eli Lilly and Company's financial disclosures for 2024 indicate a total consolidated revenue of approximately US$45.04 billion.
As of 2024, Eli Lilly and Company's global workforce comprised approximately 47,000 individuals.
Answer: True
Explanation: In the year 2024, Eli Lilly and Company reported a global workforce numbering approximately 47,000 employees.
Based on its market capitalization, Eli Lilly and Company is recognized as one of the most valuable pharmaceutical companies globally, not the least.
Answer: True
Explanation: Market capitalization data indicates that Eli Lilly and Company ranks among the most valuable pharmaceutical firms worldwide, contradicting the assertion that it is the least valuable.
Eli Lilly and Company ranks as the 100th largest company on the Fortune 500 list, not within the top 50.
Answer: True
Explanation: According to the Fortune 500 rankings, Eli Lilly and Company is positioned as the 100th largest company, which is outside the top 50.
What was the reported consolidated revenue for Eli Lilly and Company in the fiscal year 2024?
Answer: US$45.04 billion
Explanation: Eli Lilly and Company reported a consolidated revenue of US$45.04 billion for the fiscal year 2024.
In 2024, what was the approximate global employee count for Eli Lilly and Company?
Answer: 47,000
Explanation: As of 2024, Eli Lilly and Company employed approximately 47,000 individuals worldwide.
By revenue, what is Eli Lilly and Company's approximate ranking among the world's largest biomedical companies?
Answer: 11th
Explanation: Eli Lilly and Company ranks approximately 11th among the world's largest biomedical companies based on revenue.
In 2009, Eli Lilly and Company incurred a substantial penalty of $1.415 billion, encompassing a criminal fine, related to the illegal marketing of Zyprexa.
Answer: True
Explanation: Eli Lilly and Company faced significant legal repercussions in 2009, agreeing to a $1.415 billion penalty, which included a criminal fine, due to illegal marketing practices concerning Zyprexa.
In 2005, Eli Lilly and Company paid a $36 million penalty after pleading guilty to charges concerning the illegal promotion of Evista for unapproved therapeutic applications.
Answer: True
Explanation: Eli Lilly and Company paid $36 million in 2005, following a guilty plea related to the illegal promotion of Evista for uses not authorized by regulatory bodies.
In August 2025, the state of Texas initiated a lawsuit against Eli Lilly, alleging that the company engaged in bribery of healthcare providers to encourage the prescription of Mounjaro and Zepbound.
Answer: True
Explanation: A lawsuit was filed by Texas in August 2025, accusing Eli Lilly of allegedly bribing healthcare providers to prescribe Mounjaro and Zepbound.
Eli Lilly and Company initiated a NAFTA lawsuit against Canada concerning drug patents, seeking $500 million in damages, but ultimately lost the case in 2017.
Answer: True
Explanation: Eli Lilly and Company pursued a NAFTA lawsuit against Canada regarding drug patents, seeking substantial damages, but the case concluded with a loss for the company in 2017.
In 2021, Eli Lilly faced a federal lawsuit alleging age discrimination against older applicants, alongside a separate accusation of sex discrimination and creation of a hostile work environment.
Answer: True
Explanation: In 2021, Eli Lilly was involved in federal litigation addressing allegations of age discrimination against older applicants, as well as claims of sex discrimination and a hostile work environment.
In 2021, Eli Lilly challenged a U.S. Department of Health and Human Services advisory opinion concerning drug pricing under the 340B Drug Pricing Program, specifically regarding contract pharmacies.
Answer: True
Explanation: Eli Lilly contested a 2021 U.S. Department of Health and Human Services opinion related to the 340B Drug Pricing Program, focusing on the pricing structure for contract pharmacies.
The $515 million criminal fine imposed on Eli Lilly in 2009 for marketing Zyprexa was, in fact, the largest criminal fine for a corporation in a U.S. prosecution at that time.
Answer: True
Explanation: The $515 million criminal fine levied against Eli Lilly in 2009 for Zyprexa marketing practices was, at the time, the largest such fine imposed on a corporation in the United States.
What was the aggregate penalty Eli Lilly and Company agreed to pay in 2009 concerning the illegal marketing of Zyprexa?
Answer: $1.415 billion
Explanation: In 2009, Eli Lilly and Company agreed to pay a total penalty of $1.415 billion related to the illegal marketing of Zyprexa.
In which year did Eli Lilly and Company plead guilty and pay $36 million for the illegal promotion of Evista?
Answer: 2005
Explanation: Eli Lilly and Company pleaded guilty and paid $36 million in 2005 concerning the illegal promotion of Evista.
What was the ultimate outcome of the NAFTA lawsuit filed by Eli Lilly and Company against Canada concerning drug patents?
Answer: Eli Lilly lost the case in 2017.
Explanation: Eli Lilly and Company's NAFTA lawsuit against Canada concerning drug patents concluded with a loss for the company in 2017.
Which specific allegations were central to the discrimination lawsuits filed against Eli Lilly and Company in 2021?
Answer: Sex discrimination and creation of a hostile work environment.
Explanation: In 2021, Eli Lilly faced lawsuits alleging sex discrimination and the creation of a hostile work environment, alongside claims of age discrimination.
What was the core issue in the dispute between Eli Lilly and the U.S. Department of Health and Human Services (HHS) concerning the 340B Drug Pricing Program in 2021?
Answer: The dispute concerned whether manufacturers must offer reduced pricing to contract pharmacies serving hospitals.
Explanation: The dispute between Eli Lilly and HHS in 2021 centered on whether manufacturers were obligated to provide reduced pricing under the 340B program to contract pharmacies serving hospitals.
The global headquarters of Eli Lilly and Company is situated in London, United Kingdom.
Answer: False
Explanation: The global headquarters of Eli Lilly and Company is located in Indianapolis, Indiana, United States, not London, United Kingdom.
In 2024, 67% of Eli Lilly and Company's revenues were generated within the United States, with the remaining 33% originating internationally.
Answer: True
Explanation: The financial data for 2024 indicates that 67% of Eli Lilly and Company's revenue was derived from domestic operations in the United States.
During World War II, Eli Lilly and Company prioritized the production of essential medical supplies, including penicillin and merthiolate, and cooperated in processing blood plasma, rather than focusing on non-essential cosmetic items.
Answer: True
Explanation: During World War II, Eli Lilly and Company's efforts were directed towards producing critical medical supplies and assisting with blood plasma processing, not non-essential goods.
During the mid-20th century, Eli Lilly and Company strategically diversified its business interests to include agricultural chemicals and veterinary medicine products, among other areas.
Answer: True
Explanation: In the mid-20th century, Eli Lilly and Company expanded its portfolio through diversification into sectors such as agricultural chemicals and veterinary medicine.
Eli Lilly and Company directs its funding towards medical research institutions, professional medical societies, and health-focused charities, rather than primarily funding political campaigns and lobbying efforts.
Answer: True
Explanation: Eli Lilly and Company's financial contributions are primarily directed towards advancing medical research and supporting health-related charitable organizations.
Eli Lilly and Company reportedly allocates between $6 million and $10 million annually for lobbying activities within the United States.
Answer: True
Explanation: Annual reports indicate that Eli Lilly and Company expends an estimated $6 million to $10 million on lobbying efforts in the United States.
In which city and country is the global headquarters of Eli Lilly and Company situated?
Answer: Indianapolis, Indiana, United States
Explanation: The global headquarters for Eli Lilly and Company is located in Indianapolis, Indiana, within the United States.
What proportion of Eli Lilly and Company's total revenue in 2024 was generated within the United States?
Answer: 67%
Explanation: In 2024, 67% of Eli Lilly and Company's revenue originated from its operations within the United States.
What was Eli Lilly and Company's specific role in processing blood plasma during World War II?
Answer: They cooperated with the American Red Cross to process blood plasma.
Explanation: During World War II, Eli Lilly and Company collaborated with the American Red Cross in the vital process of handling blood plasma.
Into which of the following sectors did Eli Lilly and Company NOT diversify during the mid-20th century?
Answer: Consumer electronics
Explanation: During the mid-20th century, Eli Lilly and Company diversified into areas like agricultural chemicals and veterinary medicine, but not consumer electronics.
What is the approximate annual expenditure of Eli Lilly and Company on lobbying activities within the United States?
Answer: $6 million - $10 million
Explanation: Eli Lilly and Company reportedly spends between $6 million and $10 million annually on lobbying efforts in the United States.